623 related articles for article (PubMed ID: 25278674)
1. Eligibility of persons who inject drugs for treatment of hepatitis C virus infection.
Arain A; Robaeys G
World J Gastroenterol; 2014 Sep; 20(36):12722-33. PubMed ID: 25278674
[TBL] [Abstract][Full Text] [Related]
2. Hepatitis C virus control among persons who inject drugs requires overcoming barriers to care.
Zeremski M; Zibbell JE; Martinez AD; Kritz S; Smith BD; Talal AH
World J Gastroenterol; 2013 Nov; 19(44):7846-51. PubMed ID: 24307778
[TBL] [Abstract][Full Text] [Related]
3. Prevention, treatment and care of hepatitis C virus infection among people who inject drugs.
Bruggmann P; Grebely J
Int J Drug Policy; 2015 Feb; 26 Suppl 1():S22-6. PubMed ID: 25245939
[TBL] [Abstract][Full Text] [Related]
4. Integrated treatment of hepatitis C virus infection among people who inject drugs: study protocol for a randomised controlled trial (INTRO-HCV).
Fadnes LT; Aas CF; Vold JH; Ohldieck C; Leiva RA; Chalabianloo F; Skurtveit S; Lygren OJ; Dalgård O; Vickerman P; Midgard H; Løberg EM; Johansson KA;
BMC Infect Dis; 2019 Nov; 19(1):943. PubMed ID: 31703669
[TBL] [Abstract][Full Text] [Related]
5. Recommendations for the management of hepatitis C virus infection among people who inject drugs.
Robaeys G; Grebely J; Mauss S; Bruggmann P; Moussalli J; De Gottardi A; Swan T; Arain A; Kautz A; Stöver H; Wedemeyer H; Schaefer M; Taylor L; Backmund M; Dalgard O; Prins M; Dore GJ;
Clin Infect Dis; 2013 Aug; 57 Suppl 2():S129-37. PubMed ID: 23884061
[TBL] [Abstract][Full Text] [Related]
6. Research priorities to achieve universal access to hepatitis C prevention, management and direct-acting antiviral treatment among people who inject drugs.
Grebely J; Bruneau J; Lazarus JV; Dalgard O; Bruggmann P; Treloar C; Hickman M; Hellard M; Roberts T; Crooks L; Midgard H; Larney S; Degenhardt L; Alho H; Byrne J; Dillon JF; Feld JJ; Foster G; Goldberg D; Lloyd AR; Reimer J; Robaeys G; Torrens M; Wright N; Maremmani I; Norton BL; Litwin AH; Dore GJ;
Int J Drug Policy; 2017 Sep; 47():51-60. PubMed ID: 28683982
[TBL] [Abstract][Full Text] [Related]
7. Recommendations for the management of hepatitis C virus infection among people who inject drugs.
Grebely J; Robaeys G; Bruggmann P; Aghemo A; Backmund M; Bruneau J; Byrne J; Dalgard O; Feld JJ; Hellard M; Hickman M; Kautz A; Litwin A; Lloyd AR; Mauss S; Prins M; Swan T; Schaefer M; Taylor LE; Dore GJ;
Int J Drug Policy; 2015 Oct; 26(10):1028-38. PubMed ID: 26282715
[TBL] [Abstract][Full Text] [Related]
8. Hepatitis C virus treatment as prevention in people who inject drugs: testing the evidence.
Hickman M; De Angelis D; Vickerman P; Hutchinson S; Martin NK
Curr Opin Infect Dis; 2015 Dec; 28(6):576-82. PubMed ID: 26524330
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of scaling-up HCV prevention and treatment in the United States for people who inject drugs.
Barbosa C; Fraser H; Hoerger TJ; Leib A; Havens JR; Young A; Kral A; Page K; Evans J; Zibbell J; Hariri S; Vellozzi C; Nerlander L; Ward JW; Vickerman P
Addiction; 2019 Dec; 114(12):2267-2278. PubMed ID: 31307116
[TBL] [Abstract][Full Text] [Related]
10. Are Interferon-Free Direct-Acting Antivirals for the Treatment of HCV Enough to Control the Epidemic among People Who Inject Drugs?
Lima VD; Rozada I; Grebely J; Hull M; Lourenco L; Nosyk B; Krajden M; Yoshida E; Wood E; Montaner JS
PLoS One; 2015; 10(12):e0143836. PubMed ID: 26633652
[TBL] [Abstract][Full Text] [Related]
11. Hepatitis C virus testing, liver disease assessment and treatment uptake among people who inject drugs pre- and post-universal access to direct-acting antiviral treatment in Australia: The LiveRLife study.
Bajis S; Grebely J; Hajarizadeh B; Applegate T; Marshall AD; Ellen Harrod M; Byrne J; Bath N; Read P; Edwards M; Gorton C; Hayllar J; Cock V; Peterson S; Thomson C; Weltman M; Jefferies M; Wood W; Haber P; Ezard N; Martinello M; Maher L; Dore GJ;
J Viral Hepat; 2020 Mar; 27(3):281-293. PubMed ID: 31698545
[TBL] [Abstract][Full Text] [Related]
12. Priorities and recommended actions for how researchers, practitioners, policy makers, and the affected community can work together to improve access to hepatitis C care for people who use drugs.
Day E; Broder T; Bruneau J; Cruse S; Dickie M; Fish S; Grillon C; Luhmann N; Mason K; McLean E; Trooskin S; Treloar C; Grebely J
Int J Drug Policy; 2019 Apr; 66():87-93. PubMed ID: 30743093
[TBL] [Abstract][Full Text] [Related]
13. Hepatitis C virus treatment in people who inject drugs (PWID) in Bangladesh.
Rahman M; Janjua NZ; Shafiq TKI; Chowdhury EI; Sarker MS; Khan SI; Reza M; Faruque MO; Kabir A; Anis AH; Azim T
Int J Drug Policy; 2019 Dec; 74():69-75. PubMed ID: 31542689
[TBL] [Abstract][Full Text] [Related]
14. Estimating the cascade of hepatitis C testing, care and treatment among people who inject drugs in Australia.
Iversen J; Grebely J; Catlett B; Cunningham P; Dore GJ; Maher L
Int J Drug Policy; 2017 Sep; 47():77-85. PubMed ID: 28578863
[TBL] [Abstract][Full Text] [Related]
15. Opportunistic treatment of hepatitis C virus infection (OPPORTUNI-C): study protocol for a pragmatic stepped wedge cluster randomized trial of immediate versus outpatient treatment initiation among hospitalized people who inject drugs.
Midgard H; Finbråten AK; Malme KB; Berg-Pedersen RM; Tanum L; Olsen IC; Bjørnestad R; Dalgard O
Trials; 2020 Jun; 21(1):524. PubMed ID: 32539853
[TBL] [Abstract][Full Text] [Related]
16. Hepatitis C virus reinfection after successful treatment with direct-acting antiviral therapy in a large population-based cohort.
Rossi C; Butt ZA; Wong S; Buxton JA; Islam N; Yu A; Darvishian M; Gilbert M; Wong J; Chapinal N; Binka M; Alvarez M; Tyndall MW; Krajden M; Janjua NZ;
J Hepatol; 2018 Nov; 69(5):1007-1014. PubMed ID: 30142429
[TBL] [Abstract][Full Text] [Related]
17. Modeling indicates efficient vaccine-based interventions for the elimination of hepatitis C virus among persons who inject drugs in metropolitan Chicago.
Echevarria D; Gutfraind A; Boodram B; Layden J; Ozik J; Page K; Cotler SJ; Major M; Dahari H
Vaccine; 2019 May; 37(19):2608-2616. PubMed ID: 30962092
[TBL] [Abstract][Full Text] [Related]
18. Injecting risk behaviours following treatment for hepatitis C virus infection among people who inject drugs: The Australian Trial in Acute Hepatitis C.
Alavi M; Spelman T; Matthews GV; Haber PS; Day C; van Beek I; Walsh N; Yeung B; Bruneau J; Petoumenos K; Dolan K; Kaldor JM; Dore GJ; Hellard M; Grebely J;
Int J Drug Policy; 2015 Oct; 26(10):976-83. PubMed ID: 26115881
[TBL] [Abstract][Full Text] [Related]
19. Hepatitis C Reinfection in People Who Inject Drugs in Resource-Limited Countries: A Systematic Review and Analysis.
Muller A; Vlahov D; Akiyama MJ; Kurth A
Int J Environ Res Public Health; 2020 Jul; 17(14):. PubMed ID: 32659974
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the Efficacies of Direct-Acting Antiviral Treatment for HCV Infection in People Who Inject Drugs and Non-Drug Users.
Hsu JT; Hsu PI; Shie CB; Chuah SK; Wu IT; Huang WW; Tang SY; Tsai KF; Kuo LF; Ghose S; Hsu JC; Shih CA
Medicina (Kaunas); 2022 Mar; 58(3):. PubMed ID: 35334612
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
